Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Cause of Severe Genetic Disease Identified

By Goethe University Frankfurt | February 2, 2018

Mutations in the p63 protein lead to a number of disorders, but none is as severe as the AEC syndrome. Scientists at Goethe University Frankfurt in collaboration with a research group from the University of Naples Federico II have now discovered that this syndrome resembles diseases such as Alzheimer’s, Parkinson’s or ALS more closely than it does other p63-based syndromes. Their results, which were recently published in the scientific journal Proceedings of the National Academy of Sciences (PNAS), lay some groundwork for the development of new therapies.

The origin of many diseases lies in genetic abnormalities that result in malfunctions in the proteins they are encoding. A well-known und extensively studied example is p53, the tumour suppressor protein. Inactivation of p53 is one of the first stages in the development of a tumour. Mutations in the homologous protein p63, however, lead to a group of syndromes characterised by defects in embryonic development.

The transcription factor p63 functions in the stem cells of the upper skin (epidermis) and regulates their development and proliferation. Mutations in a certain part of the protein are responsible for the life-threatening disorder ankyloblepharon-ectodermal dysplasia-clefting (AEC), which is characterised, for example, by cleft palate and long-lasting skin erosions similar to severe burns. Some symptoms can be remedied or alleviated through surgery, but so far an approach to treat the cause has not been possible due to a lack of knowledge about the mutated p63 molecules.

The mutations that cause the AEC syndrome cluster in two domains of the p63 protein and do not overlap with those of the other syndromes associated to it. Since these domains are known to be a platform for protein-protein interactions, it has to date been assumed that the disorder is triggered through a loss of those interactions.

“Instead, we were able to show that mutations within p63 expose hydrophobic amino acid sequences that attach to each other in the cell and form large unstructured complexes. This leads to the loss of p63’s function as a stem cell factor,” explains Professor Volker Dötsch from the Institute of Biophysical Chemistry at Goethe University Frankfurt. Similar types of protein aggregates also cause other diseases, such as Parkinson’s, Alzheimer’s or ALS.

A wide variety of biochemical, biophysical and cell biological methods as well as a mouse model of the disorder were necessary to decipher this novel mechanism in detail. A success that was only possible thanks to close and interdisciplinary collaboration with the research group led by Professor Caterina Missero at the University of Naples Federico II. The researchers were also able to show that p63 regains its activity once the formation of aggregates is blocked. The research therefore opens up promising new avenues for treating the causes of the AEC syndrome.


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE